Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...

Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

Rocatinlimab achieved a 32.8% EASI-75 response at week 24, but fell short of market leader Dupixent’s results. Uplizna improved MG-ADL and QMG scores significantly, offering potential as a ...

Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating today. David Risinger has ...

Rocatinlimab could achieve $4 billion in sales by 2035, despite mixed trial results, due to a favorable safety profile and convenience. Uplizna shows significant sales potential in generalized ...

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...

Bank of America Securities analyst Charlie CY Yang has maintained their neutral stance on AMGN stock, giving a Hold rating today. Charlie CY ...

HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis (eczema) in 726 patients. Amgen reported that rocatinlimab outperformed a placebo regarding the severity and extent of the disease.